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Abstract
Background: Hepatitis C virus is a major cause of chronic liver diseases which can lead to permanent liver
damage, hepatocellular carcinoma and death. The presently available treatment with interferon plus ribavirin, has
limited benefits due to adverse side effects such as anemia, depression, fatigue, and “flu-like” symptoms. Herbal
plants have been used for centuries against different diseases including viral diseases and have become a major
source of new compounds to treat bacterial and viral diseases.
Material: The present study was design to study the antiviral effect of Glycyrrhizin (GL) against HCV. For this
purpose, HCV infected liver cells were treated with GL at non toxic doses and HCV titer was measured by
Quantitative real time RT-PCR.
Results and Discussion: Our results demonstrated that GL inhibit HCV titer in a dose dependent manner and
resulted in 50% reduction of HCV at a concentration of 14 ± 2 μg. Comparative studies were made with interferon
alpha to investigate synergistic effects, if any, between antiviral compound and interferon alpha 2a. Our data
showed that GL exhibited synergistic effect when combined with interferon. Moreover, these results were verified
by transiently transfecting the liver cells with HCV 3a core plasmid. The results proved that GL dose dependently
inhibit the expression of HCV 3a core gene both at mRNA and protein levels while the GAPDH remained constant.
Conclusion: Our results suggest that GL inhibit HCV full length viral particles and HCV core gene expression or
function in a dose dependent manner and had synergistic effect with interferon. In future, GL along with interferon
will be better option to treat HCV infection.
Background
Hepatitis C virus (HCV) is a major cause of liver asso-
ciated diseases all over the world. An estimated 3% of
the world’s populations, (more than 350 million people)
are chronically infected by HCV, which is the main
cause of liver fibrosis, cirrhosis and hepatocellular carci-
noma (HCC) [1]. Like other RNA viruses, HCV possess
a high degree of sequence variability that likely contri-
butes to its ability to establish chronic infections after a
mild acute phase. Current treatment of standard for
HCV comprises a combination of high-dose pegylated
interferon alpha (IFN-a) with the guanosine analogue
ribavirin (Rib). About 75% of patients receive no thera-
peutic benefit from the current combination therapy
with PEG-IFN a and the guanosine analog ribavirin
because of adverse side effects and high cost [2]. Vac-
cine development is hindered by the lack of good in-
vitro and in-vivo models of infection, the antigenic het-
erogeneity of the virus and its ability to avoid immune
defenses. Hence, there is a need to develop antiviral
drug to treat Hepatitis infection from plant sources.
The HCV is an enveloped positive-stranded RNA
virus belonging to the Hepacivirus genus of the Flaviviri-
dae family. HCV has six major genotypes and approxi-
mately 100 subtypes depending on the geographical
distribution of the virus [3]. HCV genome encodes a
single polyprotein precursor of approximately 3000
amino acid residues replicated in the cytosol through a
negative-strand intermediate. An internal ribosome
e n t r ys i t e( I R E S )d r i v e st r a n s lation of the polyprotein,
which is co- and post-translationally processed by cellu-
lar and viral proteases to yield mature viral structural
proteins Core, E1 and E2, and nonstructural proteins
NS2, NS3, NS4A, NS4B, NS5A and NS5B, while an
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meshift in the N-terminal region of the polyprotein
[4,5]. HCV structural proteins (core, E1 and E2) and
nonstructural proteins (NS3 protease and NS5B RNA-
dependent RNA polymerase) are potent molecular tar-
gets of new antiviral compounds.
Glycyrrhiza glabra is a perennial herb, native to cen-
tral and South-Western Asia, as well as to the Mediter-
ranean region and is cultivated in temperate and sub-
tropical regions of the world, including Europe and
Asia. Dried roots of Glycyrrhiza glabra have a character-
istic odour and sweet taste. It has anti-inflammatory,
antioxidant and immunomodulatory activities. Glycyr-
rhizin is the major component of Glycyrrhiza glabra
root, at concentrations of 1-9%. Glycyrrhizin is a glyco-
sylated saponin, containing one molecule of glycyrretinic
acid, with structural similarities to hydrocortisone, and
two molecules of glucuronic acid [6,7]. It has been
attributed to numerous pharmacologic effects like anti-
inflammatory, anti-viral, anti-tumor, and hepatoprotec-
tive activities [8]. It has been shown that GL inhibited
the inflammation in mice model of liver injury [9].
The present study was undertaken to study the effect
of GL against HCV 3a in liver cells. We report here that
GL effectively inhibited HCV full length viral particles
and HCV 3a Core gene RNA and protein expression in
a dose-dependent manner in Huh-7 cells.
Material and Methods
Serum Sample Collection
The local HCV-3a patient’s serum samples used in this
investigation were obtained from the CAMB (Center for
Applied Molecular Biology) diagnostic laboratory,
Lahore, Pakistan. Serum samples were stored at -80°C
prior to viral inoculation experiments. Quantification
and genotype was assessed by CAMB diagnostic labora-
tory, Lahore, Pakistan. Patient’s written consent and
approval for this study was obtained from institutional
ethics committee.
Cell line
The Huh-7 cell line was offered by Dr. Zafar Nawaz
(Biochemistry and Molecular Biology Department, Uni-
versity of Miami, USA). Huh-7 cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum & 100 IU/ml peni-
cillin & 100 μg/ml streptomycin, at 37°C in an
atmosphere of 5% CO2.
Plasmid construction
For the construction of expression plasmid, viral RNA
was isolated from 100 μl serum aliquots using Gentra
RNA isolation kit (Gentra System Pennsylvania, USA)
according to the manufacturer’s instructions. 100-200
ng extracted viral RNA was used for RT-PCR using the
SuperScript III one-step RT-PCR system (Invitrogen Life
technologies, USA). HCV complementary DNA (cDNA)
encoding the full length Core protein (amino acid 1-191
of HCV-3a) were amplified and cloned into pCR3.1
mammalian expression plasmid (kindly provided by Dr.
Zafar Nawaz, University of Miami, USA) with Flag TAG
inserted at the 5’ end of the Core gene with EcoRV and
XbaI restriction sites.
Cellular toxicity through Trypan blue dye explosive
method
Trypan blue dye was used for confirmation of viability
of Huh-7 and CHO cells. For toxicological analysis of
GL, liver cells were seeded at a density of 3 × 10
5 in six
well plate. First well was considered as control and
added different concentrations of the GL from lowest to
highest in the remaining wells. After 24 h trypsinized
the cells, prepared a suspension of 1:1 of the cell sus-
pension to trypan blue dye and dispensed 10 μlo fi to n
a glass slide and counted viable cells through
haemocytometer.
Anti-HCV analysis of Glycyrrhizin on Huh-7 cells
Huh-7 cell line was used to establish the in-vitro repli-
cation of HCV. A similar protocol was used for viral
inoculation as established by Zekari et al. 2009 [10] and
El-Awardy et al. 2006 [11]. High viral titer > 1 × 10
8
IU/ml from HCV-3a patient’s was used as principle
inoculum in these experiments. Huh-7 cells were main-
tained in 6-well culture plates to semi-confluence,
washed twice with serum-free medium, then inoculated
with 500 μl( 5×1 0
7IU/well) and 500 μl serum free
media. Cells were maintained overnight at 37°C in 5%
CO2. Next day, adherent cells were washed three times
with 1× PBS, complete medium was added and incuba-
tion was continued for 48 hrs. Cells were harvested and
assessed for viral RNA quantification by Real Time PCR.
To analyze the effect of GL on HCV infection, serum
infected Huh-7 cells were again seeded after three days
of infection in 24-well plates in the presence and
absence of GL and grown to 80% confluence with 2 ml
medium. After 24 h, cells and total RNA was isolated by
using Gentra RNA isolation kit (Gentra System Pennsyl-
vania, USA) according to the manufacturer’si n s t r u c -
tions. Briefely, cells were lysed with cell lysis solution
containing 5 μl internal control (Sacace Biotechnologies
Caserta, Italy). RNA pallet was solubilized in 1% DEPC
(Diethyl pyrocarbonate treated water). HCV RNA quan-
tifications were determined by Real Time PCR Smart
Cycler II system (Cepheid Sunnyvale, USA) using the
Sacace HCV quantitative analysis kit (Sacace Biotechnol-
ogies Caserta, Italy) according to the manufacturer’s
instructions.
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Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3STD/Res
Fam.STD/Res
× coefﬁcient IC = IUHCV/mL
IC = internal control, which is specific for each lot.
Antiviral activity of GL against HCV 3a core gene
For transfection studies, Huh-7 cells (5 × 10
4)w e r ep l a -
ted in 24-well plates for 24 h. The medium was
removed and cells were washed with 1× PBS. Cells were
transiently transfected with expression plasmids contain-
ing HCV 3a core gene (0.4 μg )i nt h ep r e s e n c ea n d
absence of GL by using Lipofectamine™ 2000 (Invitro-
gen life technologies, Carlsbad, CA) according to the
manufacturer’sp r o t o c o l .T o t a lR N Aw a se x t r a c t e db y
using Trizol reagent (Invitrogen life technologies, Carls-
bad, CA) according to the manufacturer’sp r o t o c o l .T o
analyze the effect of GL against HCV 3a core gene,
cDNA was synthesized with 1 μg of RNA, using Revert
Aid TM First Strand cDNA Synthesis Kit (Fermentas,
St. Leon-Rot/Germany). Gene expression analysis was
carried out via PCR (Applied Biosystems Inc, USA) by
using 2X PCR Mix (Fermentas). Following primers were
used for the amplification of HCV Core forward primer:
GGACGACGATGACAAGGACT; HCV core reverse:
GGCTGTGACCGTTCAGAAGT; GAPDH Forward:
ACCACAGTCCATGCCATCAC: and GAPDH reverse;
TCCACCACCCTGTTGCTGTA PCR was performed by
initial denaturation at 95°C for 5 min followed by 30
cycles, each of denaturation at 92°C for 45s, annealing
at 58°C for 45 s, and extension at 72°C for 1 min, with
final extension at 72°C for 10 min. The amplified DNA
samples were analyzed on 2% agarose gel. The DNA
bands were visualized directly under the UV and the
photographs of the gels were obtained with gel docu-
mentation system.
Western Blotting
To determine the protein expression levels of HCV
Core, the transfected and non-transfected cells were
lysed with ProteoJET mammalian cell lysis reagent (Fer-
mentas, Canada). Equal amounts of total protein were
subjected to electrophoresis on 12% SDS-PAGE and
electrophoretically transferred to a nitrocellulose mem-
brane following the manufacturer’s protocol (Bio-Rad,
CA). After blocking non-specific binding sites with 5%
skimmed milk, blots were incubated with primary
monoclonal antibodies specific to HCV Core and
GAPDH (Santa Cruz Biotechnology Inc, USA) and sec-
ondary Horseradish peroxidase-conjugated anti-goat
anti-mouse antibody (Sigma Aldrich, USA). The protein
expressions were evaluated using chemiluminescence’s
detection kit (Sigma Aldrich, USA).
Results
Toxicological study of GL in liver and fibroblast cells
Cytotoxic effects of GL was analyzed after 24 h incuba-
tion of Huh-7 and CHO cells with the concentration of
3.125, 6.25, 12.5, 25, 50 and 100 μg/ml. Cell viability
was evaluated using a viability dye and counting the
cells through haemocytometer. Figure 1 shows cytotoxi-
city analysis of GL and demonstrates that Huh7 and
CHO cells viability is unaffected up to a concentration
of 100 μg. However, when exceeds from 100 μg, toxic
effect in liver and fibroblast cells were observed. The
data verified by microscopic examination of cells and
MTT cell proliferation assay demonstrate that GL has
no toxic effect at 100 μg concentration (data not
shown).
Antiviral effect of GL against HCV
To determine the antiviral effect of GL, Huh-7 cells
were plated at the density of 3 × 10
5 cells in six well
plates. After 24 h, cells were infected with 2 × 10
5 HCV
virus copies of 3a genotype in the presence and absence
of different concentrations of GL. Cells were incubated
at 37°C in CO2 incubator for additional 24 h. At the
end of the incubation, cells were lysed with cell lysis
solution. Total RNA was extracted through Gentra RNA
isolation kit and HCV titer was determined with real
time RT PCR through HCV specific labeled primer. The
results of our study demonstrate that GL has antiviral
effect against HCV in a dose-dependent manner (Figure
2). Real time RT-PCR results exhibited that GL resulted
in 50% reduction of HCV at a concentration of 14 ± 2
μg. At a 40 μg concentration, viral inhibition of GL
reached up to 89%.
Figure 1 Toxicological study of GL in Huh-7 and CHO cell: Huh-
7 and CHO cells were plated at the density of 4 × 10
4 in six well
plates. After 24 h cells were treated with different concentrations of
GL and control consisted of solvent in which compound is disolved.
After 24 h incubation period cells were trypsinized and counted
with haemocytometer and trypan blue dye explosive method.
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After the dose response analysis, the synergistic effect of
GL was checked along with interferon. Cells were
seeded at 2 × 10
4 cells per well in 96-well plates in
DMEM medium supplemented with 10% FBS and pre-
incubated for 24 h. Cells were then treated with 10 IU
IFN-alpha 2b for 6 h and were incubated with HCV 3a
for additional 18 h. The effect of the compound was
tested with or without interferon and viral titers were
quantified through Quantitative RT-PCR. Figure 3
shows that GL exhibited 55% reduction in viral titer
alone but when GL was combined with interferon, it
resulted in 95% reduction in viral titer.
Antiviral effect of GL against HCV Core gene
To determine the antiviral effect against HCV core gene,
Huh-7 cells were transfected with HCV core gene in the
presence and absence of different concentrations of GL.
After 24 h, RNA was extracted through Triazol (Invitro-
gen). cDNA were generated by oligo dT primer. cDNA
was amplified by PCR using primers specific to the
H C Vc o r eg e n eo f3 ag e n o t y p e .A m p l i f i c a t i o no f
GAPDH mRNA served as an internal control. Figure 4
demonstrates that GL inhibits HCV RNA and protein
expression significantly in a dose-dependent manner,
while GAPDH mRNA and protein expression remains
unaffected by the addition of the GL.
Discussion
HCV infection is a serious global health problem neces-
sitating effective treatment. Currently, there is no vac-
cine available for prevention of HCV infection due to
Figure 2 Dose dependent inhibition of GL against HCV 3a
genotype. Huh 7 cells were infected with 2 × 10
5 copies of HCV 3a
genotype per well in the absence and presence of different
concentrations of GL. After 24 h incubation period, total RNA was
extracted by Gentra kit, and the levels of HCV RNA remaining were
determined by real time Quantitative RT-PCR assay and are shown
as percentage of HCV RNA survival in cells. P value > 0.05 vs control
was considered as statistically significant.
Figure 3 Synergy in the antiviral activity of GL along with
interferon. GL shows synergistic effect with interferon-a (5 IU/well)
against HCV in liver cells (Huh-7). Huh-7 cells were incubated for 6 h
with GL and interferon alone, or combination of GL and interferon
in a 96-well plate. After 6 h cells were infected with 2 × 10
4 copies
of HCV 3a genotype per well and incubated for additional 18 h. At
the end of incubation period, total RNA was extracted by Gentra kit,
and the levels of HCV RNA remaining were determined, by real time
Quantitative RT-PCR assay and are shown as percentage of HCV
RNA survival in cells. Results are represented as the average and
standard error for three independent experiments. *P value > 0.05
vs control.
Figure 4 Dose dependent inhibition of GL against HCV core
gene. Huh-7 cells were transfected with Core in the presence and
absence of different concentration of GL. (A) After 24 h incubation
period, total RNA was extracted and the levels of HCV core gene
were determined by RT-PCR. GAPDH serve as internal control. (B)
After 48 h incubation period, protein were isolated and analyzed by
western blotting with anti -Core monoclonal antibody and GAPDH
served as internal control.
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care, Pegylated interferon a in combination with riba-
virin is costly, has significant side effects and fails to
cure about half of all infections [12,13]. Hence, there is
a need to develop anti-HCV agents, both from herbal
and synthetic chemistry, which are less toxic, more effi-
cacious and cost-effective. Previous studies demon-
strated that medicinal plants used for centuries against
different diseases including viral diseases and become a
focal point to identify, isolate and purify of new com-
pounds to treat diseases such as Hepatitis. Many tradi-
tional medicinal plants and herbs were reported to have
strong antiviral activity against DNA and RNA viruses
by inhibiting virus replication, interfering with virus-to-
cell binding and immunomodulation action [14,15].
HCV structural proteins (core, E1 and E2) and non-
structural proteins (NS3 protease and NS5B RNA-
dependent RNA polymerase) are potent molecular tar-
gets of new antiviral compounds.
GL (licorice root extract) has anti-inflammatory and
antioxidant activities. GL inhibits CD4+ T-cell and
tumor necrosis factor (TNF)-mediated cytotoxicity [16].
GL has a membrane stabilizing effect [17] and also sti-
mulates endogenous production of interferon [18]. 18-b
glycyrrhetinic acid, an active constituent of Glycyrrhizic
acid shows antiviral activity against a number of DNA
and RNA viruses possibly due to activation of NFB
and induction of IL-8 secretion [19]. GL has been used
in Japan for more than 20 years orally and as the intra-
venous drug Stronger Neo-Minophagen C (SNMC).
Oral GL is metabolized in the intestine to a compound
called glycyrrhetinic acid (GA) and intravenous GL is
metabolized into glycyrrhetinic acid when excreted
through the bile into the intestines. GL and glycyrrheti-
nic acid have both been tested against Hepatitis A, B,
C–with some interesting results [20-22]. Previous stu-
dies report that GL has antiviral activity against HIV by
inhibiting virus replication, interfering with virus-to-cell
binding and cell-to-cell infection, and inducing IFN
activity [23,24]. GL has reported antiviral effect against
Herpesviridae family viruses (VZV, HSV-1, EBS, CMV)
and Flaviviruses by inhibiting the replication of virus
[7,25]. GL has also antiviral effect against some emer-
ging viruses such as SARS by inhibiting the virus repli-
cation and production of NO synthase [26] The results
of our study show that GL has antiviral effect against
HCV at non toxic concentrations. Firstly, GL was
checked for toxicological analysis in both Huh-7 and
CHO cell lines. Our data shows that GL is non toxic at
concentrations up to 100 μg (Figure 1). The data was
further verified by microscopic examination of cells and
MTT cell proliferation assay [27].
Guha et al. [28] reported that in vitro cell culture
models can at best demonstrate the infectivity of the
virus and used in evaluating drugs for antiviral activity
or inhibition of HCV infection. Most of the studies all
over the world are conducted in Huh-7 derived cell
lines and with replicons supporting HCV RNA tran-
scription and protein synthesis. Recently different
groups have studied the HCV replication in serum
infected liver cell lines for the study of different HCV
genotypes which mimics the naturally occurring HCV
virions biology and kinetics of HCV infection in humans
[29,30]. We infected Huh-7 cells with native viral parti-
cles from HCV 3a positive serum, the most prevalent
type in Pakistan using the same protocol as established
[29]. The results of our data demonstrate that GL has
antiviral effect against HCV in a dose-dependent man-
ner (Figure 2). The results prove that GL showed 50%
reduction of HCV at a concentration of 13 μg. At a con-
centration of 40 μg, viral inhibition by the GL reached
up to 85%.
HCV Core protein modulates gene transcription, cell
proliferation, cell death and cell signaling, interferes
with metabolic genes and suppresses host immune
response [31] leading to oxidative stress, liver steatosis
and eventually hepatocellular carcinoma [32]. Core pro-
tein is also able to up-regulate cyclooxygenase-2 (Cox-2)
expression in hepatocytes derived cells, providing a
potential mechanism for oxidative stress [33]. The
expression of Cox-2 in HCC was found to correlate
with the levels of several key molecules implicated in
carcinogenesis such as inducible nitric oxide synthetase
(iNOS), activate vascular endothelial growth factor
(VEGF) and phosphorylated Akt (p-Akt) [34,35]. Our
data shows that GL inhibits HCV core gene expression
or function in a dose-dependent manner similar to
interferon alpha 2a. This may be due to stimulation of
interferon pathway by phosphorylation of Stat1 on tyro-
sine and serine [36]. GL may show antiviral effect due
to its ability to reduce membrane fluidity [37] and up
regulation of Cox2 or related pathway.
Conclusion
GL inhibits HCV full length viral particle and HCV core
gene expression both at RNA and protein level and had
synergistic effect with interferon. Therefore, it can also
be speculated from our pilot study that therapeutic
induction of GL either alone or in combination with
IFN treatment might represent an alternative approach
for future treatment of chronic infection.
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